Azenta IncAZTA
▲ PositiveCapitalrelevance
Reports 9% organic revenue growth and strong performance, with non-GAAP EPS of $0.16 and share repurchases.
Impact on stocks 1
Biotech & Genomic Medicine
Azenta IncAzenta Inc reported total revenue of $161 million for the third quarter of fiscal 2026, up 12% as reported and 9% organically year-over-year, driven by strong performance in biorepositories and its C&I business. Sample Management Solutions revenue reached $88 million, up 14% reported and 9% organically, while Multiomics revenue was $73 million, up 10% reported and 8% organically. Gross margin declined 140 basis points to 46.2%, with Sample Management gross margin down 750 basis points to 45.9% due to lower volumes and quality remediation costs, partially offset by a 550-basis-point improvement in Multiomics gross margin to 46.5%. Adjusted EBITDA margin was approximately 11.4%, down 60 basis points year-over-year but up 610 basis points sequentially, and non-GAAP EPS came in at $0.16. The company repurchased approximately 2.3 million shares for $50 million and ended the quarter with $529 million in cash and marketable securities. For the full year, Azenta expects revenue in the range of $613 million to $618 million, with organic revenue approximately flat to up 1%, and adjusted EBITDA between $59 million and $62 million.
Azenta IncReports 9% organic revenue growth and strong performance, with non-GAAP EPS of $0.16 and share repurchases.